Company Overview - Boundless Bio is a clinical-stage oncology company focused on developing therapies targeting extrachromosomal DNA (ecDNA) to treat oncogene amplified cancers, which affect over 14% of cancer patients [3] - The company is headquartered in San Diego, CA and aims to address significant unmet needs in cancer therapeutics [3] Product Development - Boundless Bio is developing its first ecDNA-directed therapy (ecDTx), BBI-355, an oral inhibitor of checkpoint kinase 1 (CHK1), currently in a Phase 1/2 clinical trial for patients with oncogene amplified cancers [3] - The second ecDTx, BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) being evaluated in a Phase 1/2 clinical trial for colorectal cancer patients with BRAFV600E or KRASG12C mutations and resistance gene amplifications [3] - The company is also advancing an additional program (ecDTx 3) through preclinical development and discovery using its Spyglass platform [3] Upcoming Events - Zachary Hornby, President and CEO of Boundless Bio, will participate in Piper Sandler's 36th Annual Healthcare Conference on December 4, 2024, at 3:30 p.m. ET in New York, NY [1][2] - A live and archived webcast of the session will be available on Boundless Bio's website [2]
Boundless Bio to Participate in the Piper Sandler Healthcare Conference